Plus Therapeutics Announces New Employment Inducement Grants

Core Viewpoint - Plus Therapeutics, Inc. has granted option awards to its new Director of Capital Markets and Investor Relations, Charles Huang, to incentivize his employment with the company [1][2]. Group 1: Option Awards Details - The approved option awards allow Mr. Huang to purchase up to 5,000 shares of the company's common stock [2]. - The options will vest over four years, with one-fourth vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments [2]. - The exercise price of the options is set at the closing price of the company's common stock on the grant date, May 8, 2024 [2]. Group 2: Alignment of Interests - The company believes that these equity grants create a strong alignment of interests between Mr. Huang and the shareholders [3]. - The equity awards were granted outside of the company's 2020 Incentive Plan but have terms consistent with that plan [3]. - A Form S-8 has been filed covering these equity awards [3]. Group 3: Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers [4]. - The company aims to enhance clinical outcomes for patients through a combination of image-guided local beta radiation and targeted drug delivery approaches [4]. - Plus Therapeutics has a pipeline of product candidates, with lead programs in recurrent glioblastoma and leptomeningeal metastases, and has established a supply chain through strategic partnerships [4].